Market Overview - The medical services sector increased by 0.56% on November 25, with ST Zhongzhu leading the gains [1] - The Shanghai Composite Index closed at 3870.02, up 0.87%, while the Shenzhen Component Index closed at 12777.31, up 1.53% [1] Top Gainers in Medical Services - ST Zhongzhu (600568) closed at 2.57, up 4.90% with a trading volume of 53,900 shares and a turnover of 13.85 million yuan [1] - Chengda Pharmaceutical (301201) closed at 47.78, up 2.97% with a trading volume of 112,700 shares and a turnover of 540 million yuan [1] - Boji Pharmaceutical (300404) closed at 10.10, up 2.75% with a trading volume of 108,600 shares and a turnover of 10.9 million yuan [1] Top Losers in Medical Services - Jiuzhou Pharmaceutical (603456) closed at 18.75, down 0.85% with a trading volume of 181,100 shares and a turnover of 343 million yuan [2] - Tongce Medical (600763) closed at 41.95, down 0.66% with a trading volume of 49,600 shares and a turnover of 210 million yuan [2] - Yingkang Life (300143) closed at 10.12, down 0.49% with a trading volume of 44,700 shares and a turnover of 4.56 million yuan [2] Capital Flow Analysis - The medical services sector experienced a net outflow of 113 million yuan from institutional investors, while retail investors saw a net inflow of 30.37 million yuan [2][3] - Major stocks like WuXi AppTec (603259) had a net inflow of 67.13 million yuan from institutional investors, while Sunshine Nuohua (688621) saw a net outflow of 2.29 million yuan from retail investors [3] Summary of Individual Stock Performance - Sunshine Nuohua (688621) had a net inflow of 38.24 million yuan from institutional investors, but a net outflow of 3.59 million yuan from retail investors [3] - Chengda Pharmaceutical (301201) also saw a significant net inflow of 36.45 million yuan from institutional investors, with a net outflow of 13.58 million yuan from retail investors [3] - New Mileage (002219) had a net inflow of 14.15 million yuan from institutional investors, while retail investors experienced a net outflow of 6.70 million yuan [3]

Market Overview - The medical services sector experienced a decline of 2.71% on November 21, with Baihua Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3834.89, down 2.45%, while the Shenzhen Component Index closed at 12538.07, down 3.41% [1] Stock Performance - Notable gainers included Yangguang Nuohua, which rose by 4.47% to a closing price of 61.21, with a trading volume of 86,300 shares and a transaction value of 530 million [1] - Baihua Pharmaceutical saw a significant decline of 9.67%, closing at 9.06, with a trading volume of 292,400 shares and a transaction value of 275 million [2] - Other notable decliners included Chengda Pharmaceutical (-9.58%), Berry Genomics (-8.67%), and Guangzheng Eye Hospital (-7.26%) [2] Capital Flow - The medical services sector experienced a net outflow of 1.325 billion in institutional funds, while retail investors saw a net inflow of 1.332 billion [2] - The table of capital flow indicates that major stocks like Yangguang Nuohua had a net inflow of 10.986 million from institutional investors, while retail investors had a net inflow of 1.374 million [3]

光正眼科医院集团股份有限公司 证券代码：002524 证券简称：光正眼科 公告编号：2025-073 光正眼科医院集团股份有限公司 2025 年第三次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1.会议召开的日期、时间： 1、本次股东大会未出现否决议案的情况； 现场会议时间为：2025 年 11 月 14 日（星期五）下午 14:30； 2、本次股东大会不涉及变更以往股东大会已通过的决议； 网络投票时间为：2025 年 11 月 14 日。其中：通过深圳证券交易所交易系 统进行网络投票的具体时间为 2025 年 11 月 14 日 9:15—9:25,9:30—11:30 和 13:00—15:00；通过深圳证券交易所互联网投票系统投票的具体时间为 2025 年 11 月 14 日 9:15—15:00 期间的任意时间。 一、 会议召开情况 3.会议的召开方式：本次股东大会采取现场投票与网络投票相结合的方式； 4.会议召集人：公司第六届董事会； 5.会议主持人：董事长周永麟； 6.会议的召集、召开符合《中华人民共和国公司法 ...

T&P 新疆天阳律师事务所 光正眼科 2025 年度第三次临时股东会 新疆天阳律师事务所 关于光正眼科医院集团股份有限公司 2025 年度第三次临时股东会 法律意见书 天阳证股字[2025]第 43 号 新疆天阳律师事务所 二○二五年十一月 地址：新疆乌鲁木齐市水磨沟区红光山路 888 号绿城广场写字楼 2A 座 7 层 1 T&P 新疆天阳律师事务所 光正眼科 2025 年度第三次临时股东会 新疆天阳律师事务所 关于光正眼科医院集团股份有限公司 2025 年度第三次临时股东会 法律意见书 天阳证股字[2025]第 43 号 致：光正眼科医院集团股份有限公司 新疆天阳律师事务所（下称"本所"）接受光正眼科医院集团股份有限公司 （下称"公司"）的委托，委派本所康晨律师、尹杰律师出席公司 2025 年度第 三次临时股东会，根据《中华人民共和国公司法》（下称"《公司法》"）、《中 华人民共和国证券法》（下称"《证券法》"）、《上市公司股东会规则》和《光 正眼科医院集团股份有限公司章程》（下称"《公司章程》"），按照律师行业 公认的业务标准、道德规范和勤勉尽责精神，对有关的文件和事实进行核查与验 证，并出具法律意见。 ...

Core Viewpoint - Guangzheng Eye Hospital announced that neither the company nor its subsidiaries have provided guarantees to any units or individuals outside the scope of the consolidated financial statements, and there are no overdue debts related to guarantees, litigation guarantees, or guarantees arising from judgments against the company [1] Summary by Categories - **Company Guarantees** - The company has not provided any guarantees to entities or individuals outside the consolidated financial statements [1] - **Debt and Litigation Status** - There are no overdue debts associated with guarantees, nor are there any guarantees related to litigation or judgments against the company [1]

Core Viewpoint - The company plans to apply for a comprehensive credit line of up to 650 million yuan from financial institutions by 2025, with a total guarantee amount of 497 million yuan, which represents 441.07% of the latest audited net assets attributable to the parent company [1] Group 1 - The company and its subsidiaries will provide a cumulative guarantee limit of no more than 650 million yuan, valid for 12 months [1] - The wholly-owned subsidiary, Guangzheng New Vision, has initiated a financing lease business of 10 million yuan, with the company providing joint liability guarantees [1] - New Vision Eye Hospital has applied for a credit limit of 20 million yuan, with the company and Guangzheng New Vision providing joint liability guarantees [1]

光正眼科医院集团股份有限公司 截至本公告披露日，光正眼科医院集团股份有限公司（以下简称"公司"） 及控股子公司对外担保总额超过最近一期经审计（归母）净资产 100%，均为公 司、控股子公司、全资子公司及其下属公司间互相担保。敬请投资者关注担保风 险。 证券代码：002524 证券简称：光正眼科 公告编号：2025-072 光正眼科医院集团股份有限公司 关于下属子公司综合授信及担保事项的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 近日，公司全资子公司上海光正新视界眼科医院投资有限公司（以下简称 "光正新视界"）下属子公司上海新视界中兴眼科医院有限公司（以下简称"中 兴眼科"）与江苏金融租赁股份有限公司签署了《融资租赁合同》，中兴眼科通 过江苏金融租赁股份有限公司以售后回租方式开展融资租赁业务，融资总额为人 民币 1,000 万元，融资期限为 24 个月。公司为中兴眼科的上述融资回租业务提 供了连带责任担保。 公司全资子公司上海光正新视界眼科医院投资有限公司（以下简称"光正新 视界"）下属子公司上海新视界眼科医院有限公司（以下简称"新视界 ...

Core Viewpoint - Guangzheng Ophthalmology's stock price has shown a year-to-date increase of 24.73%, indicating positive market sentiment despite a recent decline in revenue [2] Financial Performance - As of September 30, 2025, Guangzheng Ophthalmology reported a revenue of 663 million yuan, a year-on-year decrease of 5.05%, while net profit attributable to shareholders was 173,400 yuan, reflecting a significant year-on-year growth of 100.83% [2] - The company has cumulatively distributed 14.75 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [3] Stock Market Activity - On October 31, Guangzheng Ophthalmology's stock rose by 2.02%, reaching 4.54 yuan per share, with a trading volume of 35.62 million yuan and a turnover rate of 1.55% [1] - The net inflow of main funds was 595,600 yuan, with large orders accounting for 14.03% of purchases and 12.36% of sales [1] Shareholder Structure - As of September 30, 2025, the number of shareholders decreased by 11.99% to 38,700, while the average circulating shares per person increased by 14.07% to 13,186 shares [2] - Notable changes in institutional holdings include an increase in shares held by Noan Multi-Strategy Mixed A and the entry of Jinyuan Shun'an Yuanqi Flexible Allocation Mixed as a new major shareholder [3]

Core Viewpoint - Guangzheng Eye Hospital, established in December 2001 and listed in December 2010, operates in the domestic ophthalmology medical service sector with a chain operation model, possessing brand and scale advantages [1] Group 1: Business Performance - In Q3 2025, Guangzheng Eye Hospital reported revenue of 663 million yuan, ranking 12th in the industry, significantly lower than the top player Aier Eye Hospital's 17.484 billion yuan and the industry average of 2.966 billion yuan [2] - The main business composition includes cataract projects generating 148 million yuan (33.82%) and refractive projects generating 143 million yuan (32.71%) [2] - The net profit for the same period was 380,000 yuan, ranking 11th in the industry, far behind Aier Eye Hospital's 3.367 billion yuan and the industry average of 290 million yuan [2] Group 2: Financial Ratios - As of Q3 2025, Guangzheng Eye Hospital's debt-to-asset ratio was 89.56%, up from 80.68% year-on-year, significantly higher than the industry average of 46.74%, indicating substantial debt pressure [3] - The gross profit margin for Q3 2025 was 36.41%, slightly down from 36.90% year-on-year but still above the industry average of 31.10%, reflecting a competitive profitability position [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 11.99% to 38,700, while the average number of circulating A-shares held per shareholder increased by 14.07% to 13,200 [5] - Among the top ten circulating shareholders, Noan Multi-Strategy Mixed A ranked third with 3.6956 million shares, an increase of 1.3827 million shares from the previous period [5]

Core Viewpoint - On October 27, a total of 10 listed companies had their restricted shares unlocked, with a total market value of approximately 18.54 billion yuan [1] Summary by Category Restricted Share Unlocking - Xiamen Bank (601187) extended the lock-up period for 1.348 billion shares [1] - Guangzheng Eye Hospital (002524) released 2.2245 million shares under equity incentive restrictions [1] - Shapuaisi (603168) released 30,000 shares under equity incentive restrictions [1] - Yifeng Pharmacy (603939) released 195,000 shares under equity incentive restrictions [1] - Jihong Co., Ltd. (002803) released 1.98 million shares under equity incentive restrictions [1] - Mingyang Circuit (300739) released 1.2387 million shares under equity incentive restrictions [1] - Arrow Home (001322) released 800 million shares under pre-issue restrictions [1] - Ruichen Environmental Protection (301273) released 3.70125 million shares under pre-issue restrictions [1] - Jinchengzi (688291) released 6.9 million shares [1] - Weice Technology (688372) released 2.70328 million shares [1]